EP1100455A1 - Kosmetische und dermatologische zubereitungen mit einem wirksamen gehalt an gallensäuren, ihren salzen und/oder ihren derivaten - Google Patents

Kosmetische und dermatologische zubereitungen mit einem wirksamen gehalt an gallensäuren, ihren salzen und/oder ihren derivaten

Info

Publication number
EP1100455A1
EP1100455A1 EP99938295A EP99938295A EP1100455A1 EP 1100455 A1 EP1100455 A1 EP 1100455A1 EP 99938295 A EP99938295 A EP 99938295A EP 99938295 A EP99938295 A EP 99938295A EP 1100455 A1 EP1100455 A1 EP 1100455A1
Authority
EP
European Patent Office
Prior art keywords
salts
derivatives
acid
skin
preparations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99938295A
Other languages
German (de)
English (en)
French (fr)
Inventor
Ghita LANZENDÖRFER
Volker Schreiner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beiersdorf AG
Original Assignee
Beiersdorf AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beiersdorf AG filed Critical Beiersdorf AG
Publication of EP1100455A1 publication Critical patent/EP1100455A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/02Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04Dispersions; Emulsions
    • A61K8/06Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/55Phosphorus compounds
    • A61K8/553Phospholipids, e.g. lecithin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63Steroids; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/16Emollients or protectives, e.g. against radiation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q1/00Make-up preparations; Body powders; Preparations for removing make-up
    • A61Q1/02Preparations containing skin colorants, e.g. pigments
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q1/00Make-up preparations; Body powders; Preparations for removing make-up
    • A61Q1/02Preparations containing skin colorants, e.g. pigments
    • A61Q1/04Preparations containing skin colorants, e.g. pigments for lips
    • A61Q1/06Lipsticks
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q15/00Anti-perspirants or body deodorants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/001Preparations for care of the lips
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/10Washing or bathing preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00Preparations for care of the hair
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00Preparations for care of the hair
    • A61Q5/02Preparations for cleaning the hair

Definitions

  • the present invention relates to cosmetic and dermatological preparations with an effective content of bile acids, their salts and / or their derivatives and the use thereof for strengthening the barrier function of the skin.
  • the skin is the largest human organ. Among its many functions (for example for heat regulation and as a sensory organ), the barrier function that prevents the skin (and ultimately the entire organism) from drying out is probably the most important. At the same time, the skin acts as a protective device against the penetration and absorption of substances coming from outside. This barrier function is brought about by the epidermis, which as the outermost layer forms the actual protective cover against the environment. At around a tenth of the total thickness, it is also the thinnest layer of the skin.
  • the epidermis is a stratified tissue in which the outer layer, the horny layer (stratum corneum), is the important part for the barrier function. It is worn away in contact with the environment and is therefore in a constant renewal process, with fine flakes being continuously released to the outside and corneal and lipid material horned from the inside being reproduced.
  • the skin model of Elias (PM Elias, Structure and Function of the Stratum Corneum Permeability Barrier, Drug Dev. Res. 13, 1988, 97-105), which is recognized by experts today, describes the horny layer as a two-component system, similar to a brick wall ( Brick-mortar model).
  • the horny cells (corneocytes) correspond to the bricks
  • the complex lipid membrane in the intercellular spaces corresponds to the mortar.
  • This system essentially represents a physical barrier against hydrophilic substances, but due to its narrow and more-
  • the regulation of water and moisture content is one of the most important functions of the epidermal lipid membrane. However, it not only has a barrier effect against external chemical and physical influences, but also contributes to the cohesion of the horny layer.
  • the lipids of the horny layer essentially consist of ceramides, free fatty acids, cholesterol and cholesterol sulfate and are distributed over the entire horny layer.
  • the composition of these lipids is of crucial importance for the intact function of the epidermal barrier and thus for the water impermeability of the skin.
  • the barrier effect of the skin can be quantified by determining the transepidermal water loss (TEWL - transepidermal water ioss). This is the evaporation of water from the inside of the body without taking into account the loss of water when sweating.
  • the determination of the TEWL value has proven to be extremely informative and can be used to diagnose cracked or chapped skin, to determine the compatibility of chemically differently structured surfactants and the like.
  • the water content in the top layer of skin is of the utmost importance. It can be influenced to a limited extent by introducing moisture regulators.
  • Anionic surfactants which are generally components of cleaning preparations, can increase the pH value in the horny layer for a long time, which greatly hinders regenerative processes that serve to restore and renew the barrier function of the skin. In this case, a new, often very unfavorable state of equilibrium occurs in the horny layer between regeneration and the loss of essential substances through regular extraction, which significantly affects the external appearance of the skin and the physiological functioning of the horny layer.
  • Skin care in the sense of the present invention is to be understood primarily as meaning that the natural function of the skin acts as a barrier against environmental influences (e.g. dirt, chemical potassium, microorganisms) and against the loss of the body's own substances (e.g. water, lipids, electrolytes) is strengthened or restored.
  • environmental influences e.g. dirt, chemical potassium, microorganisms
  • loss of the body's own substances e.g. water, lipids, electrolytes
  • the effect of ointments and creams on the barrier function and the hydration of the horny layer is based essentially on the covering (occlusion) of the treated skin areas.
  • the ointment or cream is, so to speak, a (second) artificial barrier that is supposed to prevent water loss from the skin.
  • This physical barrier can be removed correspondingly easily, for example with cleaning agents, as a result of which the original, impaired state is reached again.
  • the skin care effect can decrease with regular treatment. After stopping the application of the product, the skin quickly returns to the condition before the start of treatment. With certain products, the condition of the skin may even temporarily deteriorate. A sustainable product effect is therefore generally not achieved or only to a limited extent.
  • the effect of nourishing cleaning products essentially consists in an efficient regreasing with sebum lipid-like substances.
  • the damage to the horny layer barrier can be further limited.
  • the prior art lacks preparations which have a positive effect on the barrier function and hydration of the horny layer and which strengthen or even restore the physicochemical properties of the horny layer and in particular the lamellae made of intercellular lipids.
  • the object of the present invention was therefore to eliminate the disadvantages of the prior art.
  • skin-care preparations and preparations for cleaning the skin should be made available which maintain or restore the barrier properties of the skin, especially when the natural regeneration of the skin is insufficient. They should also be suitable for the treatment and prophylaxis of consequential damage to skin drying out, for example fissures or inflammatory or allergic processes or also neurodermatitis.
  • barrier strengthening or “strengthening the barrier function of the skin” is to be understood in particular to mean the following effect: the active compounds according to the invention interact with the lipids of the horny layer in such a way that the arrangement of these lipids in the horny layer at the molecular level is improved. This means that the natural function of the skin as a barrier against environmental influences and against the loss of the body's own substances is strengthened or restored.
  • Bile is the exocrine secretion of the liver, the main components of which are water (86.7%), bile acids (9.1%), bile pigments (3%), cholesterol (0.3%) and fatty acids, pro teine and inorganic substances.
  • the function of the bile in the context of fat digestion consists in the emulsification of water-insoluble food components in the intestinal tract and in the conversion of water-insoluble compounds into the resorbable cholic acids.
  • the bile acids which occur in the bile as salts, keep the cholesterol in solution and facilitate its excretion.
  • Bile acids are predominantly substituted cholanic acids conjugated with glycine (glycocholic acid) or taurine (taurocholic acid), which have the following structural motif:
  • dehydrocholic acid which is characterized by the following structure, and its salts:
  • lithocholic acid which is characterized by the following structure, and its salts:
  • Cholic acid which is characterized by the following structure, and its salts are also advantageous:
  • Glycocholic acid which is characterized by the following structure, and its salts are also advantageous:
  • taurolithocholic acid which is characterized by the following structure, and its salts, in particular its sodium salt:
  • deoxycholic acid which is characterized by the following structure, and its salts:
  • ursodeoxycholic acid (chenodeoxycholic acid), which is characterized by the following structure, and its salts:
  • taurocholic acid which is characterized by the following structure, and its salts, in particular its sodium salt:
  • esters and ethers of bile acids are also advantageous in the sense of the present invention.
  • Bile acid ethers can be obtained by etherification of at least one of the alcohol functions in the 3-, 7- or 12-position of the cholane ring. Bile acid ethers which are obtainable by etherification of the alcohol function in the 3-position are particularly preferred.
  • bile acid ethers which are obtainable by etherification with ethylene oxide, saturated and / or unsaturated, branched and / or unbranched alcohols having a chain length of 2 to 22 carbon atoms are advantageous.
  • Bile acid esters can be obtained by esterifying at least one of the alcohol functions in the 3-, 7- or 12-position of the cholane ring and by esterifying the terminal acid functions.
  • Advantageous in the sense of the present invention are bile acid esters, which by esterification with saturated and / or unsaturated, branched and / or unbranched acids with a chain length of 2 to 22 carbon atoms are available.
  • bile acid esters which can be obtained by esterifying the terminal acid function with ethylene oxide, saturated and / or unsaturated, branched and / or unbranched alcohols with a chain length of 2 to 22 carbon atoms.
  • the salts of bile acids are also particularly advantageous in the sense of the present invention.
  • the sodium, potassium and / or triethanolamine salts of bile acids are particularly preferred according to the invention.
  • the cosmetic or dermatological preparations or formulations according to the invention can be composed as usual and can be used for the treatment, care and cleaning of the skin and / or hair and as a make-up product in decorative cosmetics. Correspondingly, depending on their structure, they can be used, for example, as a skin protection cream, cleansing milk, sunscreen lotion, nutritional cream, day or night cream, etc. It may be possible and advantageous to use the preparations according to the invention as the basis for pharmaceutical formulations.
  • the preparations according to the invention contain z. B.
  • 0.001 to 10 wt .-% preferably 0.01 wt .-% to 1 wt .-%, but especially 0.01 wt .-% to 0.5 wt .-%, each based on the total weight of the preparations on the active substances according to the invention.
  • Cosmetic and dermatological preparations which are in the form of a sunscreen are also favorable.
  • these preferably contain at least one UV-A filter substance and / or at least one UV-B filter substance and / or at least one inorganic pigment.
  • the cosmetic and dermatological preparations according to the invention can contain cosmetic auxiliaries, as are usually used in such preparations, e.g. B. preservatives, bactericides, perfumes, anti-foaming substances, dyes, pigments that have a coloring effect, thickeners, surface-active substances, emulsifiers, softening, moisturizing and / or moisturizing substances, fats, oils, waxes or other common components of a cosmetic or dermatological formulation such as alcohols, polyols, polymers, foam stabilizers, electrolytes, organic solvents or silicone derivatives.
  • cosmetic auxiliaries e.g. B. preservatives, bactericides, perfumes, anti-foaming substances, dyes, pigments that have a coloring effect, thickeners, surface-active substances, emulsifiers, softening, moisturizing and / or moisturizing substances, fats, oils, waxes or other common components of a cosmetic or dermatological formulation such as alcohols, polyo
  • Preparations for the treatment and care of the skin are particularly preferred.
  • the cosmetic and dermatological preparations according to the invention are applied to the skin and / or the hair in a sufficient amount in the manner customary for cosmetics.
  • Cosmetic and dermatological preparations according to the invention can be in various forms. So you can z. B. a solution, an anhydrous preparation, an emulsion or microemulsion of the water-in-oil (W / O) or oil-in-water (O / W) type, a multiple emulsions, for example of the water-in-oil type Oil-in-water (W / O / W), a gel, a solid stick, an ointment or an aerosol. It is also advantageous to present the active compounds according to the invention in encapsulated form, e.g. B. in collagen matrices and other common encapsulation materials, e.g. B.
  • the cosmetic and dermatological preparations according to the invention can also contain antioxidants.
  • all the antioxidants suitable or customary for cosmetic and / or dermatological applications can be used as favorable antioxidants.
  • the antioxidants are advantageously selected from the group consisting of amino acids (e.g. glycine, histidine, tyrosine, tryptophan) and their derivatives, imidazoles (e.g. urocanic acid) and their derivatives, peptides such as D, L-camosine, D-carnosine, L-carnosine and their derivatives (e.g. anserine), carotenoids, carotenes (e.g. ⁇ -carotene, ß-carotene, lycopene) and their derivatives, chlorogenic acid and its derivatives, lipoic acid and its derivatives ( e.g.
  • amino acids e.g. glycine, histidine, tyrosine, tryptophan
  • imidazoles e.g. urocanic acid
  • peptides such as D, L-camosine, D-carnosine, L-carnosine and their derivatives (e.g. anserine)
  • thiols e.g. thioredoxin, glutathione, cysteine, cystine, cystamine and their glycosyl, N-acetyl, methyl, ethyl, propyl, amyl , Butyl and lauryl, palmitoyl, oleyl, ⁇ -linoleyl, cholesteryl and glyceryl esters
  • salts dilauryl thiodipropionate, distearyl thiodipropionate, thiodipropionic acid and their derivatives (esters, ethers, peptides, lipids, nucleotides, nucleosides and salts) as well as sulfoximine compounds (e.g.
  • buthionine sulfoximines in very low tolerable doses (e.g. B. pmol to ⁇ mol / kg), further (metal) chelators (e.g. ⁇ -hydroxy fatty acids, palmitic acid, phytic acid, lactoferrin), ⁇ -hydroxy acids (e.g.
  • crtronic acid lactic acid, malic acid
  • humic acid bile acid
  • Bile extracts bilirubin, biliverdin, EDTA, EGTA and their derivatives
  • unsaturated fatty acids and their derivatives e.g. ⁇ -linolenic acid, linoleic acid, oleic acid
  • folic acid and their derivatives ubiquinone and ubiquinol and their derivatives
  • vitamin C and derivatives e.g. B. Ascorbyl palmitate, Mg ascorbyl phosphate, ascorbyl acetate), tocopherols and derivatives (e.g.
  • vitamin E acetate
  • vitamin A and derivatives vitamin A palmitate
  • Derivatives e.g. stilbene oxide, trans-stilbene oxide
  • derivatives suitable according to the invention te (salts, esters, ethers, sugars, nucleotides, nucleosides, peptides and lipids) of these active ingredients.
  • the amount of the aforementioned antioxidants (one or more compounds) in the preparations according to the invention is preferably 0.001 to 30% by weight, particularly preferably 0.05-20% by weight, in particular 1-10% by weight, based on the total weight the preparation.
  • vitamin E and / or its derivatives represent the antioxidant (s)
  • vitamin A or vitamin A derivatives or carotenes or their derivatives represent the antioxidant or antioxidants, it is advantageous to use their respective concentrations in the range from 0.001-10% by weight, based on the total weight of the formulation, to choose.
  • Color pigments Color lacquers, titanium dioxide q, p.
  • Glycerol monostearate 1 00
  • Titanium dioxide 2.50

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP99938295A 1998-08-01 1999-07-20 Kosmetische und dermatologische zubereitungen mit einem wirksamen gehalt an gallensäuren, ihren salzen und/oder ihren derivaten Withdrawn EP1100455A1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19834814 1998-08-01
DE19834814A DE19834814A1 (de) 1998-08-01 1998-08-01 Kosmetische und dermatologische Zubereitungen mit einem wirksamen Gehalt an Gallensäuren, ihren Salzen und/oder ihren Derivaten
PCT/EP1999/005157 WO2000007557A1 (de) 1998-08-01 1999-07-20 Kosmetische und dermatologische zubereitungen mit einem wirksamen gehalt an gallensäuren, ihren salzen und/oder ihren derivaten

Publications (1)

Publication Number Publication Date
EP1100455A1 true EP1100455A1 (de) 2001-05-23

Family

ID=7876163

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99938295A Withdrawn EP1100455A1 (de) 1998-08-01 1999-07-20 Kosmetische und dermatologische zubereitungen mit einem wirksamen gehalt an gallensäuren, ihren salzen und/oder ihren derivaten

Country Status (5)

Country Link
US (1) US7052716B1 (ja)
EP (1) EP1100455A1 (ja)
JP (1) JP2003526602A (ja)
DE (1) DE19834814A1 (ja)
WO (1) WO2000007557A1 (ja)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6389455B1 (en) * 1998-09-22 2002-05-14 Richard C. Fuisz Method and apparatus for bouncing electronic messages
DE10031703A1 (de) * 2000-06-29 2002-01-10 Beiersdorf Ag Verwendung von Calcium freisetzenden oder bindenden Substanzen zur gezielten Schächung oder Stärkung der Barrierefunktion der Haut
DE10107240A1 (de) * 2001-02-16 2002-08-29 Beiersdorf Ag Gelemulsionen in Form von O/W-Emulsionen mit einem Gehalt an Hydrokolloiden
US20050037040A1 (en) * 2003-08-13 2005-02-17 Moshe Arkin Topical compositions of urea and ammonium lactate
US20050036953A1 (en) * 2003-08-13 2005-02-17 Moshe Arkin Topical compositions of ammonium lactate
US20050042268A1 (en) * 2003-07-16 2005-02-24 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
US20060127468A1 (en) * 2004-05-19 2006-06-15 Kolodney Michael S Methods and related compositions for reduction of fat and skin tightening
US20080182833A1 (en) * 2005-03-17 2008-07-31 Eric Jude Joffre Silicone Emulsion, Method of Preparing Same, and Cosmetic Ingredient
DE102006013283A1 (de) * 2006-03-20 2007-09-27 Beiersdorf Ag Sprühbare Sonnenschutzlotion
US20080318870A1 (en) 2007-06-19 2008-12-25 Kythera Biopharmaceuticals, Inc. Synthetic bile acid compositions and methods
US8242294B2 (en) 2007-06-19 2012-08-14 Kythera Biopharmaceuticals, Inc. Synthetic bile acid compositions and methods
JOP20180077A1 (ar) 2007-06-19 2019-01-30 Kythera Biopharmaceuticals Inc تركيبات وطرق لحمض صفراوي تخليقي
EP2020221B1 (de) * 2007-06-19 2012-02-29 Neubourg Skin Care GmbH & Co. KG DMS (Derma Membrane Structure) in Schaum-Cremes
US8101593B2 (en) 2009-03-03 2012-01-24 Kythera Biopharmaceuticals, Inc. Formulations of deoxycholic acid and salts thereof
MX2013001704A (es) 2010-08-12 2013-06-28 Kythera Biopharmaceuticals Inc Composiciones sinteticas de acido biliar y metodos.
EP2675460A4 (en) 2011-02-18 2014-07-09 Kythera Biopharmaceuticals Inc TREATMENT OF FAT TISSUE UNDER CHIN
KR20180036580A (ko) * 2016-09-30 2018-04-09 주식회사 유스바이오팜 수가용화(水加溶化)된 우르소데옥시콜산을 함유하는 염증성 피부질환 또는 중증 소양증 예방 또는 치료용 조성물

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4115313A (en) * 1974-10-08 1978-09-19 Irving Lyon Bile acid emulsions
IT1076001B (it) * 1977-01-04 1985-04-22 Also Lab Di Dr P Sorbini & C S Composizione per il trattamento del cuoio capelluto e contro la caduta dei capelli
IT8167097A0 (it) * 1981-01-26 1981-01-26 Unilever Nv Composizione cosmetica per il trattamento della pelle o dei capelli
FR2551991B1 (fr) 1983-09-15 1989-07-28 Pernod Ricard Emulsions aqueuses d'huiles essentielles ou de matieres liposolubles et de sels biliaires et procede pour leur preparation
JPH01211596A (ja) 1988-02-18 1989-08-24 Kurita Water Ind Ltd 包接化合物
DE3814839A1 (de) * 1988-05-02 1989-11-16 Henkel Kgaa Haarbehandlungsmittel mit natuerlichen inhaltsstoffen
JPH0358918A (ja) * 1989-07-28 1991-03-14 Koog Honpo:Kk 消臭組成物
US5100662A (en) * 1989-08-23 1992-03-31 The Liposome Company, Inc. Steroidal liposomes exhibiting enhanced stability
CA2033725C (en) * 1990-01-24 2001-05-29 Folker Pittrof Pharmaceutical and cosmetic compositions containing a salt of cholanic acid
JP2740153B2 (ja) * 1995-03-07 1998-04-15 エフ・ホフマン−ラ ロシユ アーゲー 混合ミセル
DE19522694A1 (de) * 1995-06-22 1997-01-02 Vinas Jose Maria De Moragas Teerhaltige Zusammensetzung und diese enthaltende pharmazeutische und kosmetische Zubereitung
US5750104A (en) * 1996-05-29 1998-05-12 Digestive Care Inc. High buffer-containing enteric coating digestive enzyme bile acid compositions and method of treating digestive disorders therewith
KR100453351B1 (ko) 1996-07-25 2005-04-19 주식회사 엘지생활건강 구강위생증진용조성물
JPH10120579A (ja) * 1996-10-18 1998-05-12 Dokutaazu Kosumeteikusu:Kk 津液改善用皮膚外用剤
JPH10120561A (ja) * 1996-10-18 1998-05-12 Dokutaazu Kosumeteikusu:Kk 津液改善用皮膚外用剤
CA2237699C (en) * 1997-11-04 2007-10-16 Kyowa Hakko Kogyo Co., Ltd. Novel protein complexes
RU2224523C2 (ru) * 1998-07-24 2004-02-27 Сео Хонг Ю Водный раствор, содержащий желчную кислоту, и способ его получения
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0007557A1 *

Also Published As

Publication number Publication date
DE19834814A1 (de) 2000-02-03
WO2000007557A1 (de) 2000-02-17
JP2003526602A (ja) 2003-09-09
US7052716B1 (en) 2006-05-30

Similar Documents

Publication Publication Date Title
EP0934053B1 (de) Kosmetische oder dermatologische mikroemulsion
EP1406599B1 (de) Kreatin enthaltende kosmetische und dermatologische zubereitungen zur behandlung und aktiven prävention trockener haut und anderer negativer veränderungen der physiologischen homöostase der gesunden haut
DE10133202A1 (de) Osmolyte enthaltende kosmetische und dermatologische Zubereitungen zur Behandlung und aktiven Prävention trockener Haut und anderer negativer Veränderungen der physiologischen Homöostase der gesunden Haut
DE19802206A1 (de) Lipidreduzierte, fließfähige Zubereitungen
WO2000007557A1 (de) Kosmetische und dermatologische zubereitungen mit einem wirksamen gehalt an gallensäuren, ihren salzen und/oder ihren derivaten
DE19615577A1 (de) Verwendung von Salicin als antiirritativer Wirkstoff in kosmetischen und topischen dermatologischen Zubereitungen
WO2002000185A1 (de) Verwendung von calcium freisetzenden oder bindenden substanzen zur gezielten schwächung oder stärkung der barrierefunktion der haut
WO2002019973A2 (de) Lipidarme kosmetische und dermatologische zubereitungen in form von o/w-emulsionen mit einem gehalt an fettsäuren
EP2090283B1 (de) Verwendung von Elektrolyten zur Stärkung der Barrierefunktion der Haut
WO1999037273A2 (de) Kosmetische und dermatologische zubereitungen, enthaltend erhöhte elektrolytkonzentrationen
DE10133203A1 (de) Catechine oder Extrakte von grünem Tee enthaltende kosmetische und dermatologische Zubereitungen zur Behandlung und aktiven Prävention trockener Haut und anderer negativer Veränderungen der physiologischen Homöostase der gesunden Haut
DE10133200A1 (de) Carnitin enthaltende kosmetische und dermatologische Zubereitungen zur Behandlung und aktiven Prävention trockener Haut und anderer negativer Veränderungen der physiologischen Homöostase der gesunden Haut
DE102005030864A1 (de) Kosmetische Zubereitung zur Verbesserung der Hautfeuchtigkeit
DE10010199A1 (de) Wäßrig-alkoholische Zubereitungen mit einem Gehalt an Chitosan
EP0974338A2 (de) Pflegende kosmetische und dermatologische Zubereitungen mit einem Gehalt an Fettsäuren
DE19843566A1 (de) Verwendung von Wirkstoffen, gewählt aus der Gruppe der 1,2-Diacylglycerole, zur Stärkung der Barrierefunktion der Haut
EP0884048B1 (de) Kosmetische und dermatologische Emulsionen, enthaltend Alkylglucoside und erhöhte Elektrolytkonzentrationen
EP0955038B1 (de) Kosmetische und dermatologische Zubereitungen mit einem Gehalt an Ceramiden
DE10133197A1 (de) Aminosäuren enthaltende kosmetische und dermatologische Zubereitungen zur Behandlung und aktiven Prävention trockener Haut und anderer negativer Veränderungen der physiologischen Homöostase der gesunden Haut
DE19834812A1 (de) Verwendung von Sterolderivaten in kosmetischen und dermatologischen Zubereitungen zur Stärkung der Barrierefunktion der Haut
DE19962267A1 (de) Verwendung von Wirkstoffkombinationen aus einem oder mehreren NO-Synthasehemmern und einer oder mehreren Ascorbylverbindungen zur Stärkung der Barrierefunktion der Haut
DE10133196A1 (de) Nicotinsäure enthaltende kosmetische und dermatologische Zubereitungen zur Behandlung und aktiven Prävention trockener Haut und anderer negativer Veränderungen der physiologischen Homöostase der gesunden Haut
DE10133201A1 (de) Elektrolythaltige kosmetische und dermatologische Zubereitungen zur Behandlung und aktiven Prävention trockener Haut und anderer negativer Veränderungen der physiologischen Homöostase der Haut
DE19834813A1 (de) Verwendung von Glycerin- und/oder Glykolestern langkettiger, aliphatischer, verzweigter und/oder unverzweigter Fettsäuren in kosmetischen und dermatologischen Zubereitungen zur Stärkung der Barrierefunktion der Haut
DE10133195A1 (de) Biotin enthaltende kosmetische und dermatologische Zubereitungen zur Behandlung und aktiven Prävention trockener Haut und anderer negativer Veränderungen der physiologischen Homöostase der gesunden Haut

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010117

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060201